CORVEL CORP (CRVL) research
CORVEL CORP- Sector
- Health Care
- Last price
- $71.83
- As of
CORVEL CORP (CRVL): 7 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-11.
As of . Source: SEC EDGAR filings for CRVL. Method and limitations.
Share the CRVL intelligence card
See CRVL live in the terminal
Track CRVL's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live CRVL terminal, freeActive signals for CRVL
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 74% of CRVL (2026Q2)
- highINSTITUTIONAL_EXIT
D. E. Shaw & Co., Inc. cut 58% of CRVL (2026Q2)
- mediumNEW_POSITION
Bridgewater Associates, LP new position in CRVL
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 74% of CRVL (2026Q2)
- highINSTITUTIONAL_EXIT
D. E. Shaw & Co., Inc. cut 58% of CRVL (2026Q2)
FREE, NO ACCOUNT
Every signal on CRVL, as it fires
You are seeing 5 of 12 signals recorded on CRVL since 2026-07-24.
The five above all landed on 2026-09-06. The other 7 were recorded on 2 other days. 12 of the 12 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CRVL (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 221006109 · 2026Q2 | $95.6M | 0.13% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 221006109 · 2026Q2 | $9.1M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 221006109 · 2026Q2 | $6.3M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 221006109 · 2026Q2 | $4.1M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 221006109 · 2026Q2 | $2M | 0.00% | , |
| Bridgewater Associates, LPCUSIP 221006109 · 2026Q2 | $1.2M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 221006109 · 2026Q2 | $638K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CRVL
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
CRVL against its peers
CRVL's net margin of 11.5% ranks in the 83rd percentile of 25 Health Care sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | CRVL | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 959M USD | 1.9B USD | 25 | 25 |
| Revenue YoY | 7.0% | n/a | n/a | 0 |
| Gross margin | 24.3% | 59.5% | 13 | 18 |
| Operating margin | n/a | 6.4% | n/a | 24 |
| Net margin | 11.5% | 3.7% | 83 | 25 |
| Return on equity | 28.0% | 7.0% | 90 | 24 |
| P / E | 33.6x | 40.1x | 47 | 15 |
Peers (25): IRTC, OPCH, NVST, LIVN, ITGR, WGS, TMDX, AVAH, ATRC, DOCS, BKD, ACHC, WAY, HAE, MMSI, PRVA, TFX, INSP, RDNT, ALHC, MD, PGNY, SEM, HIMS, LNTH. Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (CRVL: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more CRVL signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to CRVLand get the insider, 13F, options, and confluence read in one view.